Anthony R. Mato, MD, MSCE

Exciting novel-based treatment strategies being investigated in chronic lymphocytic leukemia.

Implications for treating chronic lymphocytic leukemia with small molecule combination regimens in the frontline setting.

The rationale for investigating and using PI3K inhibitors to treat chronic lymphocytic leukemia.

Susan O’Brien, MD, and Anthony Mato, MD, MSCE, describe their preferences for treating newly diagnosed chronic lymphocytic leukemia based on disease presentation and patient variables.

The rationale for integrating CD20 monoclonal antibody therapy into the frontline setting of chronic lymphocytic leukemia.

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Frontline therapies available to treat newly diagnosed high-risk chronic lymphocytic leukemia, and the rationale for selecting a targeted therapy versus chemoimmunotherapy as initial treatment.

Reactions to an atypical diagnosis of high-risk chronic lymphocytic leukemia in a 61-year-old man.

Drs Alexey Danilov and Anthony Mato respond to a variety of questions pertaining to the assessment and treatment of patients with chronic lymphocytic leukemia.

Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.

Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.

Recommendations for conducting imaging scans and biopsies to help guide the treatment of newly diagnosed chronic lymphocytic leukemia.

The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.

Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses differences between the use of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.